|
FY2025
12 months to Dec 27, 2025
|
FY2024
12 months to Dec 28, 2024
|
FY2023
12 months to Dec 30, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 25, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Net Product Revenues | |||||
| Research and Development Revenues | |||||
| Grant Income | |||||
| Collaboration Arrangement Income | |||||
| License and Other Revenues | |||||
| Total revenues | |||||
| Expenses: | |||||
| Cost of product revenues | |||||
| Research and development-funded programs | |||||
| Research and development-Funded | |||||
| Research and development – Internal | |||||
| Selling, general and administrative | |||||
| Litigation damages | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Non-operating income (expense), net: | |||||
| Interest income | |||||
| Other income, net | |||||
| Foreign currency transaction gains | |||||
| Gain on deconsolidation of subsidiary | |||||
| Gain (loss) on investments | |||||
| Total non-operating income (expense) | |||||
| Income (loss) before provision for income taxes | |||||
| Provision for income taxes | |||||
| Net income (loss) | |||||
| Net loss attributable to Kopin Corporation | |||||
| Dividends and deemed dividends on Series A convertible preferred stock | |||||
| Net income (loss) attributable to common stockholders | |||||
| Basic | |||||
| Diluted | |||||
Loading...